RxDoctor Payments Data

Lindsey Hahn, DO

Urogynecology and Reconstructive Pelvic Surgery · Lakeland, FLNPI 1457604738

Payments from drug & device makers

$2,614in general payments, 2019–2025

Across 45 payments — averaging $58.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Caldera Medical, Inc$361
  • Medtronic$174
  • Femselect Inc.$151
  • Astellas Pharma US Inc$112
  • Novartis$63
  • plus $369 from 14 others

What the payments were for

  • Travel & lodging$75029%
  • Food & beverage$1,66964%
  • Education$853%
  • Gifts$1104%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,614 in reported general payments places this provider in the 20th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

See all urogynecology and reconstructive pelvic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$128,546
Medicare patients
254
Services billed
909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron479$261,706
PremarinEstrogens, Conjugated191$84,237
GemtesaVibegron26$23,985
LinzessLinaclotide14$8,345
Estradiol113$7,696
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst233$6,572
Trimethoprim96$4,673
Clobetasol Propionate101$3,873
Solifenacin Succinate28$3,330
Methenamine Hippurate36$1,960
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen171$1,152
Oxybutynin Chloride ErOxybutynin Chloride16$484
Estradiol (Twice Weekly)Estradiol14$412
Nystatin25$411
Metronidazole17$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$112$261,706479 claims
PfizerPremarin$35$84,237191 claims
AbbVieLinzess$36$8,34514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

Other urogynecology and reconstructive pelvic surgery in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →